{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:29:38Z","timestamp":1780921778069,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1007\/s00403-008-0831-8","type":"journal-article","created":{"date-parts":[[2008,1,31]],"date-time":"2008-01-31T08:47:06Z","timestamp":1201769226000},"page":"101-105","source":"Crossref","is-referenced-by-count":23,"title":["Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases"],"prefix":"10.1007","volume":"300","author":[{"given":"Rotraut","family":"M\u00f6ssner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Thaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"P\u00e4tzold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Peter","family":"Bertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ullrich","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,2,1]]},"reference":[{"key":"831_CR1","first-page":"178","volume":"5","author":"DR Adams","year":"2006","unstructured":"Adams DR, Buckel T, Sceppa JA (2006) Infliximab associated new-onset psoriasis. J Drugs Dermatol 5:178\u2013179","journal-title":"J Drugs Dermatol"},{"key":"831_CR2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1046\/j.1523-1747.2003.12094.x","volume":"120","author":"K Asumalahti","year":"2003","unstructured":"Asumalahti K, Ameen M, Suomela S, Hagforsen E, Michaelsson G, Evans J, Munro M, Veal C, Allen M, Leman J, David BA, Kirby B, Connolly M, Griffiths CE, Trembath RC, Kere J, Saarialho-Kere U, Barker JN (2003) Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 120:627\u2013632","journal-title":"J Invest Dermatol"},{"key":"831_CR3","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1365-2133.2004.05960.x","volume":"150","author":"S Benoit","year":"2004","unstructured":"Benoit S, Toksoy A, Brocker EB, Gillitzer R, Goebeler M (2004) Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol 150:1009\u20131012","journal-title":"Br J Dermatol"},{"key":"831_CR4","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.20155","volume":"50","author":"W Beuthien","year":"2004","unstructured":"Beuthien W, Mellinghoff HU, von Kempis J (2004) Skin reaction to adalimumab. Arthritis Rheum 50:1690\u20131692","journal-title":"Arthritis Rheum"},{"key":"831_CR5","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.jaad.2005.10.029","volume":"54","author":"W Carey","year":"2006","unstructured":"Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, Papp K, Rundle AC, Toth D (2006) Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 54:S171\u2013S181","journal-title":"J Am Acad Dermatol"},{"key":"831_CR6","first-page":"223","volume":"143","author":"GC Gannes de","year":"2007","unstructured":"de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, Shojania K, Martinka M, Dutz JP (2007) Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 143:223\u2013231","journal-title":"Arch Dermatol"},{"key":"831_CR7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/archderm.143.2.233","volume":"143","author":"DF Fiorentino","year":"2007","unstructured":"Fiorentino DF (2007) The Yin and Yang of TNF-{alpha} inhibition. Arch.Dermatol 143:233\u2013236","journal-title":"Arch.Dermatol"},{"key":"831_CR8","doi-asserted-by":"crossref","first-page":"R666","DOI":"10.1186\/ar1724","volume":"7","author":"M Flendrie","year":"2005","unstructured":"Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL (2005) Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 7:R666\u2013R676","journal-title":"Arthritis Res Ther"},{"key":"831_CR9","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","volume":"139","author":"AB Gottlieb","year":"2003","unstructured":"Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R (2003) A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139:1627\u20131632","journal-title":"Arch Dermatol"},{"key":"831_CR10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/ard.2005.037424","volume":"65","author":"S Kary","year":"2006","unstructured":"Kary S, Worm M, Audring H, Huscher D, Renelt M, Sorensen H, Stander E, Maass U, Lee H, Sterry W, Burmester GR (2006) New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis 65:405\u2013407","journal-title":"Ann Rheum Dis"},{"key":"831_CR11","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/j.1365-2133.2005.06977.x","volume":"153","author":"G Michaelsson","year":"2005","unstructured":"Michaelsson G, Kajermo U, Michaelsson A, Hagforsen E (2005) Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? Br J Dermatol 153:1243\u20131244","journal-title":"Br J Dermatol"},{"key":"831_CR12","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.0022-202X.2004.23556.x","volume":"124","author":"R M\u00f6ssner","year":"2005","unstructured":"M\u00f6ssner R, Kingo K, Kleensang A, Kruger U, Konig IR, Silm H, Westphal GA, Reich K (2005) Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J Invest Dermatol 124:282\u2013284","journal-title":"J Invest Dermatol"},{"key":"831_CR13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1365-4362.2002.01543.x","volume":"41","author":"MR Newland","year":"2002","unstructured":"Newland MR, Weinstein A, Kerdel F (2002) Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 41:449\u2013452","journal-title":"Int J Dermatol"},{"key":"831_CR14","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","volume":"366","author":"K Reich","year":"2005","unstructured":"Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366:1367\u20131374","journal-title":"Lancet"},{"key":"831_CR15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2133.2004.05719.x","volume":"150","author":"K Schmick","year":"2004","unstructured":"Schmick K, Grabbe J (2004) Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab). Br J Dermatol 150:367","journal-title":"Br J Dermatol"},{"key":"831_CR16","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/art.21233","volume":"52","author":"PP Sfikakis","year":"2005","unstructured":"Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A (2005) Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 52:2513\u20132518","journal-title":"Arthritis Rheum"},{"key":"831_CR17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s00296-004-0567-5","volume":"25","author":"MJ Starmans-Kool","year":"2005","unstructured":"Starmans-Kool MJ, Peeters HR, Houben HH (2005) Pustular skin lesions in patients treated with infliximab: report of two cases. Rheumatol Int 25:550\u2013552","journal-title":"Rheumatol Int"},{"key":"831_CR18","first-page":"439","volume":"3","author":"M Thurber","year":"2004","unstructured":"Thurber M, Feasel A, Stroehlein J, Hymes SR (2004) Pustular psoriasis induced by infliximab. J Drugs Dermatol 3:439\u2013440","journal-title":"J Drugs Dermatol"},{"key":"831_CR19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.eye.6702262","volume":"21","author":"BJ Wegscheider","year":"2007","unstructured":"Wegscheider BJ, El Shabrawi L, Weger M, Ardjomand N, Hermann J, Aberer E, El Shabrawi Y (2007) Adverse skin reactions to infliximab in the treatment of intraocular inflammation. Eye 21:547\u2013549","journal-title":"Eye"},{"key":"831_CR20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00403-006-0707-8","volume":"298","author":"U Mrowietz","year":"2006","unstructured":"Mrowietz U, Elder JT, Barker J (2006) The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 298:309\u2013319","journal-title":"Arch Dermatol Res"},{"key":"831_CR21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00403-007-0744-y","volume":"299","author":"A Nast","year":"2007","unstructured":"Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B (2007) German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 299:111\u2013138","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"831_CR22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00403-006-0660-6","volume":"298","author":"KA Papp","year":"2006","unstructured":"Papp KA (2006) The long-term efficacy and safety of new biological therapies for psoriasis. Arch.Dermatol.Res 298(1):7\u201315","journal-title":"Arch.Dermatol.Res"},{"key":"831_CR23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00403-006-0703-z","volume":"298","author":"DM Sommer","year":"2006","unstructured":"Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M (2006) Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 298:321\u2013328","journal-title":"Arch Dermatol Res"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-008-0831-8.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,7]],"date-time":"2019-04-07T05:11:06Z","timestamp":1554613866000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00403-008-0831-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,1]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["831"],"URL":"https:\/\/doi.org\/10.1007\/s00403-008-0831-8","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,1]]}}}